검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CIK cell therapy (CIK cell therapy) Shenzhen Hornetcorn Bio-technology…·Non Small Cell Lung Cancer 54 trials |
|---|---|
Overview Program | CIK cell therapy |
Overview Company | Shenzhen Hornetcorn Bio-technology Company, LTD |
Overview Modality | CGT |
Overview Target | Non Small Cell Lung Cancer |
Overview Indication | Non Small Cell Lung Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | target BL cells via the Fas-FasL axis rather than the NKG2D pathway |
MoA Biomarker | PD-1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.. Clear cell renal cell carcinoma (ccRCC) remains a challenging malignancy to treat, with immune checkpoint inhibitors (ICIs) revolutionizing patient management. This pilot study, evaluated the efficacy and safety of combination therapy comprising camrelizum… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 21 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CIK cell therapy (CIK cell therapy) Shenzhen Hornetcorn Bio-technology…·Non Small Cell Lung Cancer 54 trials |
|---|---|
Overview Program | CIK cell therapy |
Overview Company | Shenzhen Hornetcorn Bio-technology Company, LTD |
Overview Modality | CGT |
Overview Target | Non Small Cell Lung Cancer |
Overview Indication | Non Small Cell Lung Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | target BL cells via the Fas-FasL axis rather than the NKG2D pathway |
MoA Biomarker | PD-1 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.. Clear cell renal cell carcinoma (ccRCC) remains a challenging malignancy to treat, with immune checkpoint inhibitors (ICIs) revolutionizing patient management. This pilot study, evaluated the efficacy and safety of combination therapy comprising camrelizum… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 21 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교